Cesarean Scar Diverticula Clinical Trial
Official title:
Comparison of the Therapeutic Effects of Vaginal Repair and Vaginal Repair Combined With GnRHa in the Treatment of Cesarean Scar Diverticula: a Randomized Clinical Trial
Cesarean scar diverticula (CSD) is a novel recognized cause of postmenstrual abnormal uterine bleeding in women. No clinical guidelines have been issued for the management of CSD. The investigators have previously demonstrated that vaginal repair of CSD was an relative effective treatment of CSD. However, only 28.2% of the CSD patients normalized to less than 7 days of menstruation, whereas 51.2% of women had 7 to 10 days of menstruation at 6 months post vaginal repair. Postoperative menstruation may contribute to surgical site infections, which may subsequently affect the healing of uterine scars. Treatment CSD patients with gonadotropin-releasing hormone agonist (GnRHa) may has the potential to improve therapeutic effects of vaginal repair. Therefore, the current multiple-center randomized controlled trial was designed to evaluate whether the application of GnRHa in combination with vaginal repair could achieve better clinical effects than those achieved by vaginal CSD repair alone.
Status | Not yet recruiting |
Enrollment | 220 |
Est. completion date | July 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 40 Years |
Eligibility |
Inclusion Criteria: 1. Patients are younger than 40. 2. Clearly diagnosed with CSD. 3. Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 7 days). 4. The thickness of the remaining muscular layer of CSD was less than 3 mm. 5. The women are at least 20 years old with singleton pregnancies and had undergone a cesarean delivery after at least 37 weeks of gestation. 6. The medicine conservative treatment is invalid. 7. Refusing or use birth control pills contraindications. 8. No serious medical problems (important viscera function in the normal range). 9. No uterine fibroids, endometriosis, adenomyosis, and patients with ovarian cysts. 10. No gynaecology or other malignant tumors. 11. Sign the informed consent. Exclusion Criteria: 1. Over the age of 40; 2. Indefinite diagnosis. 3. The absence of clinical manifestations of CSD. 4. The presence of menstrual irregularities before cesarean delivery. 5. Coagulation disorders. 6. Malignant tumors. 7. With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs). 8. Known chronic inflammatory diseases, any other uterine diseases (such as uterine fibroids, endometriosis and adenomyosis), uterine surgery except cesarean section. 9. Use of intrauterine devices. 10. Unwilling to comply with the research plan. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Department of Gynecology, Shanghai First Maternity and Infant Hospital, affiliated to Tongji University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Xipeng Wang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | thickness of the remaining muscular layer (mm) | The thickness of the remaining muscular layer is measured by transvaginal ultrasound. | 6 months after vaginal repair of CSD | No |
Primary | duration of menstruation (day) | The menstruation duration in CSD patients is collected 6 months after vaginal repair of CSD. | 6 months after vaginal repair of CSD | No |
Secondary | the length of CSD (mm) | The length of CSD is measured by transvaginal ultrasound. | 6 months after vaginal repair of CSD | No |
Secondary | the width of CSD (mm) | The width of CSD is measured by transvaginal ultrasound. | 6 months after vaginal repair of CSD | No |
Secondary | the depth of CSD (mm) | The depth of CSD is measured by transvaginal ultrasound. | 6 months after vaginal repair of CSD | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02933216 -
Comparison of the Therapeutic Effects of VR and Hysteroscope + Laparoscope in the Treatment of Cesarean Scar Diverticula
|
N/A |